ClinicalTrials.gg
Status unknownNCT04113941Updated Jul 28, 2020

Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder

A Phase 3 interventional study of Neuronox and Placebo in Overactive Bladder, sponsored by Medy-Tox. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.

Sponsored by Medy-Tox · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive — 3 open to participants now, 5 under way, 1 of them phase 3. botulinum toxin type A · Urinary Bladder, Overactive.

Enrollment
13th of 44
216 · median 84
Started
2019
with 4 others
Phase 3
16 of 44
none open now
Registered
34th of 44
by date
Lead sponsor
2 of 44
Medy-Tox

Among the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, this one is the 13th largest by enrollment, is one of 5 that started in 2019, is one of 16 in phase 3, and was the 34th registered.

Urinary Bladder, Overactive

859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

3 of the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About botulinum toxin type A

botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, or all of them as a file.
02

Study summary

This study is for patients who have idiopathic overactive bladder symptoms. This study will evaluate efficacy and safety of Neuronox® against placebo.

03

Conditions studied

  • Overactive Bladder
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged above 20
  • Patient with overactive bladder symptoms lasting at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Patient with a history of surgery or a disease that may affect bladder function.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Neuronox®

    Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites

    Drug: Neuronox

  • Placebo comparator
    Placebo

    Normal saline, same volume with Experimental arm

    Drug: Placebo

Interventions

  • intradetrusor injection

    Also known as: Meditoxin

  • DrugPlacebo

    intradetrusor injection

06

What researchers measure

Primary outcomes

  1. The change in the daily average UI (Urinary Incontinence) episodes

    Time frame: 12 weeks

07

Study locations

1 site
  • Konkuk University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Apr 2020, 7 months.

Of 26 industry-sponsored phase 3 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 16 months of starting (the median); a quarter within 11 and three quarters within 24. This study's 7 months is below that.

Counting every sponsor, half of 33 studies reached it within 18 months; a quarter within 11 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2019
First posted
Oct 3, 2019
StartActual
Aug 23, 2019
Primary completionActual
Apr 15, 2020
CompletionEst.
Aug 2021
Last update
Jul 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04113941
Lead sponsor
Medy-Tox
Responsible party
Sponsor
First posted
Oct 3, 2019
Start date
Aug 23, 2019
Primary completion
Apr 15, 2020
Completion
Aug 2021 (estimated)
Last update
Jul 28, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion